ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks Equity Research
Zacks Rank can tell you which stocks to buy and sell. Zacks Equity Research tells you why. Click here to learn more.

Quote:

Search for Ticker

Free Membership

Search:

MED: Medifast Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

MEDIFAST INC (NYSE)
MED	27.59	0.06	(0.22%)	Vol. 214,192	16:00 ET

Medifast Inc has one operating subsidiary, Jason Pharmaceuticals, Inc, its manufacturing arm. They are engaged in the production, distribution, and sale of consumable health and diet products. Their product lines include weight management, meal replacement and sports nutrition products manufactured in a modern facility in Owings Mills, Maryland.

General Information

MEDIFAST INC

11445 Cronhill Drive Owings Mills, MD 21117 Phone: 410 581-8042 Fax: 410 581-8070 Web: www.medifastdiet.com Email: ir@medifastdiet.com

Industry	FOOD-MISC/DIVERSIFIED
Sector:	Consumer Staples

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/11/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	27.53
52 Week High	28.67
52 Week Low	3.63
Beta	2.17
20 Day Moving Average	740,312.38
Target Price Consensus	31

% Price Change
4 Week	32.04
12 Week	59.97
YTD	398.73

% Price Change Relative to S&P 500
4 Week	26.99
12 Week	44.40
YTD	300.17

Share Information
Shares Outstanding (millions)	15.25
Market Capitalization (millions)	419.86
Short Ratio	2.24
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	0.19
Current Year EPS Consensus Estimate	0.80
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/11/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.00
30 Days Ago	3.00
60 Days Ago	3.00
90 Days Ago	3.00

Fundamental Ratios

P/E
Current FY Estimate:	34.41
Trailing 12 Months:	41.09
PEG Ratio	-

EPS Growth
vs. Previous Year	109.09%
vs. Previous Quarter	15.00%

Sales Growth
vs. Previous Year	64.97%
vs. Previous Quarter:	10.54%

Price Ratios
Price/Book	8.67
Price/Cash Flow	39.44
Price / Sales	2.90

ROE
09/30/09	22.88
06/30/09	19.82
03/31/09	17.29

ROA
09/30/09	17.59
06/30/09	15.08
03/31/09	12.91

Current Ratio
09/30/09	4.19
06/30/09	3.29
03/31/09	2.92

Quick Ratio
09/30/09	2.85
06/30/09	2.00
03/31/09	1.42

Operating Margin
09/30/09	6.81
06/30/09	6.28
03/31/09	5.75

Net Margin
09/30/09	10.64
06/30/09	9.61
03/31/09	8.59

Pre-Tax Margin
09/30/09	10.64
06/30/09	9.61
03/31/09	8.59

Book Value
09/30/09	3.18
06/30/09	3.06
03/31/09	2.81

Inventory Turnover
09/30/09	2.88
06/30/09	2.47
03/31/09	2.23

Debt-to-Equity
09/30/09	0.12
06/30/09	0.09
03/31/09	0.10

Debt to Capital
09/30/09	10.43
06/30/09	8.51
03/31/09	9.38


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research